Intelligent Oncolytic Virus Therapy Platform
Legal Citation
Summary of the Inventive Concept
A novel system integrating oncolytic viruses with AI, IoT, blockchain, and advanced biomaterials for personalized, adaptive, and secure cancer treatment.
Background and Problem Solved
The original patent disclosed an innovative method for enhancing the antitumor effect of oncolytic viruses using oxaliplatin. However, it had limitations in terms of personalized treatment, real-time monitoring, and secure data management. The new inventive concept addresses these limitations by integrating the patented method with cutting-edge technologies.
Detailed Description of the Inventive Concept
The Intelligent Oncolytic Virus Therapy Platform comprises five key components: (1) an oncolytic virus growth module integrated with an AI-powered genomics analysis platform, (2) IoT-enabled biosensors for real-time monitoring, (3) a blockchain-based decentralized data management system, (4) a composite biomaterial for targeted virus delivery, and (5) a machine learning model for predicting virus resistance. These components work together to provide personalized treatment regimens, adaptive virus strain selection, and secure data management.
Novelty and Inventive Step
The new claims introduce a synergistic combination of oncolytic viruses with AI, IoT, blockchain, and advanced biomaterials, which is not obvious from the original patent. The integration of these distinct technologies enables a novel system for personalized, adaptive, and secure cancer treatment.
Alternative Embodiments and Variations
Alternative embodiments may include using different AI algorithms, IoT sensor configurations, or blockchain protocols. Variations may involve incorporating additional technologies, such as CRISPR gene editing or nanotechnology, to further enhance the platform's capabilities.
Potential Commercial Applications and Market
The Intelligent Oncolytic Virus Therapy Platform has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, precision oncology, and digital health. The market for oncolytic virus therapy is expected to grow substantially in the coming years, driven by increasing demand for effective and targeted cancer treatments.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K35/768 |
| A | A61 | A61K31/282 |
| A | A61 | A61K31/4745 |
| A | A61 | A61K31/513 |
| A | A61 | A61P35/00 |
| C | C12 | C12N7/00 |
| C | C12 | C12N2770/32332 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Oncology, virology, and biomedical engineering with a focus on targeted cancer therapies involving oncolytic viruses and treatment optimization technologies
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in biomedical engineering, molecular biology, or oncology, possessing expertise in viral therapeutics, computational biology, and medical technology integration
Obviousness Rationale
A PHOSITA would recognize that the integration of AI, IoT, and blockchain technologies with oncolytic virus therapy represents a predictable extension of existing cancer treatment optimization strategies. The source patent's focus on precise virus and drug interactions naturally suggests opportunities for advanced computational and monitoring technologies. The disclosed variations demonstrate standard technological convergence in personalized medicine approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,584 |
|---|---|
| Title | Oncolytic virus growth method and antitumor agent |
| Assignee(s) | KABUSHIKI KAISHA YAKULT HONSHA |